Your browser doesn't support javascript.
[Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial "BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)"].
Mareev, V Yu; Orlova, Ya A; Pavlikova, E P; Matskeplishvili, S T; Akopyan, Z A; Plisyk, A G; Seredenina, E M; Asratyan, D A; Potapenko, A V; Malakhov, P S; Samokhodskaya, L M; Mershina, E A; Sinitsyn, V E; Bulanova, M M; Fuks, A A; Mareev, Yu V; Begrambekova, Yu L; Kamalov, A A.
  • Mareev VY; Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia School of Basic Medicine of the M. V. Lomonosov Moscow State University, Moscow, Russia.
  • Orlova YA; Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia School of Basic Medicine of the M. V. Lomonosov Moscow State University, Moscow, Russia.
  • Pavlikova EP; Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia School of Basic Medicine of the M. V. Lomonosov Moscow State University, Moscow, Russia.
  • Matskeplishvili ST; Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia.
  • Akopyan ZA; Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia School of Basic Medicine of the M. V. Lomonosov Moscow State University, Moscow, Russia.
  • Plisyk AG; Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia School of Basic Medicine of the M. V. Lomonosov Moscow State University, Moscow, Russia.
  • Seredenina EM; Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia School of Basic Medicine of the M. V. Lomonosov Moscow State University, Moscow, Russia.
  • Asratyan DA; Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia School of Basic Medicine of the M. V. Lomonosov Moscow State University, Moscow, Russia.
  • Potapenko AV; Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia School of Basic Medicine of the M. V. Lomonosov Moscow State University, Moscow, Russia.
  • Malakhov PS; Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia.
  • Samokhodskaya LM; Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia School of Basic Medicine of the M. V. Lomonosov Moscow State University, Moscow, Russia.
  • Mershina EA; Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia School of Basic Medicine of the M. V. Lomonosov Moscow State University, Moscow, Russia.
  • Sinitsyn VE; Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia School of Basic Medicine of the M. V. Lomonosov Moscow State University, Moscow, Russia.
  • Bulanova MM; School of Basic Medicine of the M. V. Lomonosov Moscow State University, Moscow, Russia.
  • Fuks AA; School of Basic Medicine of the M. V. Lomonosov Moscow State University, Moscow, Russia.
  • Mareev YV; National Medical Research Centre for Therapy and Preventive Medicine, Moscow, Russia Robertson Centre for Biostatistics, Glasgow, Great Britain.
  • Begrambekova YL; Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia School of Basic Medicine of the M. V. Lomonosov Moscow State University, Moscow, Russia.
  • Kamalov AA; Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia School of Basic Medicine of the M. V. Lomonosov Moscow State University, Moscow, Russia.
Kardiologiia ; 60(8): 4-15, 2020 Sep 07.
Article in Russian | MEDLINE | ID: covidwho-948254
ABSTRACT
The article focuses on effective treatment of the novel coronavirus infection (COVID-19) at early stages and substantiates the requirement for antiviral therapy and for decreasing the viral load to prevent the infection progression. The absence of a specific antiviral therapy for the SARS-CoV-2 virus is stated. The authors analyzed results of early randomized studies using lopinavir/ritonavir, remdesivir, and favipiravir in COVID-19 and their potential for the treatment of novel coronavirus infection. Among the drugs blocking the virus entry into cells, the greatest attention was paid to the antimalaria drugs, chloroquine and hydroxychloroquine. The article addresses in detail ineffectiveness and potential danger of hydroxychloroquine, which demonstrated neither a decrease in the time of clinical recovery nor any improvement of prognosis for patients with COVID-19. The major objective was substantiating a possible use of bromhexine, a mucolytic and anticough drug, which can inhibit transmembrane serin protease 2 required for entry of the SARS-CoV-2 virus into cells. Spironolactone may have a similar feature. Due to its antiandrogenic effects, spironolactone can inhibit X-chromosome-related synthesis of ACE-2 receptors and activation of transmembrane serin protease 2. In addition to slowing the virus entry into cells, spironolactone decreases severity of fibrosis in different organs, including the lungs. The major part of the article addresses clinical examples of managing patients with COVID-19 at the University Clinic of the Medical Research and Educational Centre of the M. V. Lomonosov Moscow State University, including successful treatment with schemes containing bromhexine and spironolactone. In conclusion, the authors described the design of a randomized, prospective BISCUIT study performed at the University Clinic of the M. V. Lomonosov Moscow State University with an objective of evaluating the efficacy of this scheme.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Spironolactone / Bromhexine / Coronavirus Infections / Pandemics Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Europa Language: Russian Journal: Kardiologiia Year: 2020 Document Type: Article Affiliation country: Cardio.2020.8.n1307

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Spironolactone / Bromhexine / Coronavirus Infections / Pandemics Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Europa Language: Russian Journal: Kardiologiia Year: 2020 Document Type: Article Affiliation country: Cardio.2020.8.n1307